Despite being designated as a “Chinese military” company by the U.S. Department of Defense, the CRDMO continues its strong growth in total revenue and net profit.
Building capacity across the radiopharmaceutical value chain is proving to be a significant challenge given the need for specialized facilities, according to the firm.
A BioMADE-funded project demonstrated programmed cell-wall lysis at pilot scale, reducing the mechanical energy required for separation by more than 50% in one yeast strain.
South Korean CDMO raises 2026 revenue guidance, as Seoul High Court extends its injunction to nine production processes at Songdo site — just days before planned strike.
The company is tapping artificial intelligence and advanced analytics to build a “cognitive CDMO” connecting scientific knowledge with operational data.
The facilities in France and Singapore were recognized for their modular, scalable, AI-enabled design, producing multiple vaccine platforms and biologics simultaneously.
Wolfgang Wienand said this week that the company is focused on its overall breadth of capabilities, serving customers across scales, regions, and the entire lifecycle.
